<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8910749</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2163</journal-id>
<journal-id journal-id-type="nlm-ta">J Neurosurg Anesthesiol</journal-id>
<journal-id journal-id-type="iso-abbrev">J Neurosurg Anesthesiol</journal-id>
<journal-title-group>
<journal-title>Journal of neurosurgical anesthesiology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0898-4921</issn>
<issn pub-type="epub">1537-1921</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29734272</article-id>
<article-id pub-id-type="pmc">6215737</article-id>
<article-id pub-id-type="doi">10.1097/ANA.0000000000000508</article-id>
<article-id pub-id-type="manuscript">NIHMS961356</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>General Anesthetic Use in Fragile X Spectrum Disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ligsay</surname>
<given-names>Andrew</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>El-Deeb</surname>
<given-names>Marwa</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Salcedo-Arellano</surname>
<given-names>Maria J</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schloemerkemper</surname>
<given-names>Nina</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Grayson</surname>
<given-names>Jeremy S.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hagerman</surname>
<given-names>Randi</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California, Davis Medical Center, Sacramento, CA, USA</aff>
<aff id="A2">
<label>2</label>University of California, Davis School of Medicine, Sacramento, CA, USA</aff>
<aff id="A3">
<label>3</label>Department of Pediatrics, University of California, Davis Medical Center, Sacramento, CA, USA</aff>
<aff id="A4">
<label>4</label>Department of Anesthesiology and Pain Medicine, University of California, Davis Medical Center, Sacramento, CA, USA</aff>
<aff id="A5">
<label>5</label>Department of Anesthesia, Rutgers University Robert Wood Johnson Medical School, New Brunswick, NJ, USA</aff>
<author-notes>
<corresp id="FN1">Corresponding Author: Randi Hagerman, MD, MIND Institute, UCDMC, 2825 50<sup>th</sup> street, Sacramento, California, 95817, Phone 916-7030257, FAX: 916-7030240, <email>rjhagerman@ucdavis.edu</email></corresp>
<fn fn-type="COI-statement" id="FN2">
<p>Conflicts: RH has received support from Novartis, Alcobra, Neuren, and Marinus for studies in fragile X syndrome. She has also consulted with Zynerba, Fulcrum and Ovid regarding studies in fragile X syndrome. The other authors report no conflicts.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>14</day>
<month>5</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>7</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>7</month>
<year>2020</year>
</pub-date>
<volume>31</volume>
<issue>3</issue>
<fpage>285</fpage>
<lpage>290</lpage>
<!--elocation-id from pubmed: 10.1097/ANA.0000000000000508-->
<abstract>
<p id="P1">The fragile X premutation is characterized by a repeat expansion mutation (between 55â€“200 CGG repeats) in the Fragile X Mental Retardation 1 (<italic>FMR1)</italic> gene, which leads to RNA toxicity at the cellular level. This may cause patients with the premutation to be particularly susceptible to environmental toxins, which could manifest clinically as new or worsening ataxia and memory loss. Multiple published case reports have also suggested general anesthetics as a potential toxin leading to negative side effects when used in patients with fragile X- associated disorders. However, at this time, there have been no formal research studies regarding cellular changes or long-term clinical manifestations after general anesthetic use in this population. This review aims to highlight previous case reports regarding sequelae related to general anesthetic use in fragile X- associated disorders. New case reports related to this phenomenon are also included.</p>
</abstract>
<kwd-group>
<kwd>FXTAS</kwd>
<kwd>fragile X syndrome</kwd>
<kwd><italic>FMR1</italic> mRNA</kwd>
<kwd>general anesthesia</kwd>
<kwd>postoperative cognitive dysfunction</kwd>
<kwd>POCD</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>